Today's Top Story

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

(Reuters) - Drugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan Plc for about $63 billion, grabbing control of the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira. Read More

 

Business News

Economic News

Money News

News, Photo and Web Search

Search News by Ticker